Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology

Sodium–glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM). Inhibition of SGLT2 leads to improved glycemic control through increased urinary glucose excretion (UGE). In this study, a biologically based pharmacokineti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Maurer, Tristan S., Ghosh, Avijit, Haddish-Berhane, Nahor, Sawant-Basak, Aarti, Boustany-Kari, Carine M., She, Li, Leininger, Michael T., Zhu, Tong, Tugnait, Meera, Yang, Xin, Kimoto, Emi, Mascitti, Vincent, Robinson, Ralph P.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2011
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3231856/
https://ncbi.nlm.nih.gov/pubmed/21870203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-011-9297-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars